鈴木 岳之 (スズキ タケシ)

Suzuki, Takeshi

写真a

所属(所属キャンパス)

薬学部 薬学科 薬学教育研究センター (芝共立)

職名

准教授

メールアドレス

メールアドレス

外部リンク

 

著書 【 表示 / 非表示

  • 疾患と薬物治療 第10章 精神疾患.

    鈴木岳之, 藤本和子, 横田恵理子, 井澤早苗., 医歯薬出版, 東京, 2008年05月

    担当範囲: 303-328

  • 通信講座テキスト 第4講座「レセプターと薬の作用機序」.

    鈴木岳之, 藤本和子., 東京/共立薬科大学, 2006年04月

    担当範囲: 1-80

  • 新しい機能形態学−ヒトの成り立ちとその働き.

    小林静子、馬場広子、平井みどり., 東京/広川書店, 2005年06月

    担当範囲: 177-184, 339-347

  • スタンダード薬学シリーズ4 生物系薬学 Ⅰ. 生命体の成り立ち 第5章 循環系.

    鈴木岳之., 東京/東京化学同人, 2005年03月

    担当範囲: 30-33

  • 受容体(レセプター)と薬の作用機序.

    鈴木岳之, 藤本和子., 東京/共立薬科大学, 2004年09月

    担当範囲: 1-

全件表示 >>

論文 【 表示 / 非表示

  • Japan oncology market overview: Current and future perspectives.

    Shibata S, Matsushita M, Suzuki T, Ozaki K.

    J Generic Med. 15 ( 3 ) 104 - 114 2019年

    研究論文(学術雑誌), 共著, 査読有り

  • Can Rare Cancer Drugs Expect Sales in Japan?: A Prescription Pattern Analysis of Drugs for Chronic Myelogenous Leukemia and Neuroendocrine Tumor.

    Shibata S, Noguchi E, Matsushita M, Suzuki T, Ozaki K.

    J Regul Sci. 7   1 - 9 2019年

    研究論文(学術雑誌), 共著

  • The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classes.

    Shibata S, Suzuki T

    J Generic Med. 14 ( 2 ) 70 - 80 2018年08月

    研究論文(学術雑誌), 共著, 査読有り

  • Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan

    Shibata S., Matsushita M., Saito Y., Suzuki T.

    Therapeutic Innovation and Regulatory Science (Therapeutic Innovation and Regulatory Science)  52 ( 4 ) 442 - 448 2018年07月

    ISSN  21684790

     概要を見る

    © The Author(s) 2017. Background: The increased use of generic drugs is a good indicator of the need to reduce the increasing costs of prescription drugs. Since there are more expensive drugs compared with other therapeutic areas, “oncology” is an important one for generic drugs. The primary objective of this article was to quantify the extent to which generic drugs in Japan occupy each level of the Anatomical Therapeutic Chemical (ATC) classification system. Methods: The dataset used in this study was created from publicly available information obtained from the IMS Japan Pharmaceutical Market database. Data on the total amount of sales and number of prescriptions for anti-cancer drugs between 2010 and 2016 in Japan were selected. The data were categorized according to the third level of the ATC classification system. Results: All categories of the ATC classification system had increased market shares in Japan between 2010 and 2016. The barriers to market entry were relatively low in L01F (platinum anti-neoplastics), L01C (plant-based neoplastics), L02B (cytostatic hormone antagonists), and L01D (anti-neoplastic antibiotics) but were high in L02A (cytostatic hormones), L01H (protein kinase inhibitors), and L01B (anti-metabolites). Conclusions: Generic cancer drugs could bring savings to Japanese health care systems. Therefore, their development should be directed toward niche markets, such as L02A, L01H, and L01B, and not competitive markets.

  • Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy

    鈴木 岳之

    Therapeutic Innovation and Regulatory Science (Therapeutic Innovation and Regulatory Science)  52 ( 6 ) 718 - 723 2018年

    研究論文(学術雑誌), 共著, 査読有り,  ISSN  21684790

     概要を見る

    © The Author(s) 2018. Background: Despite their benefits, the rapid development of new cancer treatments has been a significant driver of increasing health care expenditures in the face of limited health care budgets. In this study, we analyzed the prescribing trends for anticancer drugs from 2010 through 2016 in Japan and sought to identify unique trends that could provide a basis for future medical economic research aiming to develop more efficacious and cost-effective cancer therapies. Methods: We used publicly available marketing data for anticancer drugs in Japan for 2010-2016. The drugs selected for this research were categorized according to the Anatomical Therapeutic Chemical Classification System. We investigated the overall anticancer drug market size, the number of anticancer drugs, the top 30 selling anticancer categories, sales and prescription volumes, and changes in sales and prescription volumes between 2010 and 2016 in the country. Results: The anticancer agent market expanded each year from 2010 to 2016, with sales exceeding 1 trillion yen in 2015. The proportion of molecular targeted drugs (antineoplastic mAbs and protein kinase inhibitors) among the top 30 selling anticancer categories has continued to increase, and both the sales and prescription volumes of these drugs exceeded those of drugs in other categories, suggesting that these treatments play a dominant role in cancer pharmacotherapy. Conclusion: The availability and increasing use of innovative but more expensive targeted therapies were major drivers of increases in pharmaceutical expenditures for cancer treatment in Japan. Therefore, the effective use of genetic testing can mitigate these rising costs.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

全件表示 >>

総説・解説等 【 表示 / 非表示

  • Direct reprogramming, epigenetics, and cardiac regeneration.

    鈴木 岳之

    J Card Fail 23 ( 7 ) 552 - 557 2017年

    総説・解説(学術雑誌), 単著

研究発表 【 表示 / 非表示

  • 抗うつ薬とP2X4受容体の相互作用の比較検討.

    ○笠原由佳, 三浦麻利衣, 最上由香里, 関野祐子, 佐藤薫, 鈴木岳之.

    日本薬学会第134回年会 (熊本) , 2014年03月

  • Neural differentiation potentials in human embryonic stem cell lines.

    ○福本大悟, 松本拓也, 岡田洋平, 末盛博文, 中辻憲夫, 鈴木岳之, 赤松和土, 岡野栄之.

    第87回日本薬理学会年会 (仙台) , 2014年03月

  • 中国医薬品市場の現状と製薬企業の動向分析および今後の展開.

    ○森田和仁, 鈴木岳之.

    第57回日本薬学会関東支部大会 (東京) , 2013年10月

  • 新薬創出加算の獲得・継続に影響を及ぼす因子の解析.

    ○反町知希, 相川大輔, 中村洋, 鈴木岳之.

    第57回日本薬学会関東支部大会 (東京) , 2013年10月

  • P2X4 receptor-mediated acceleration of microglial activation is important for the L-glutamate release from activated microglia in the early stage of inflammation.

    Sato K, Fujimori K, Takaki J, Suzuki T, Sekino Y.

    Neuro2013 (京都) , 2013年06月

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 課題研究(薬学教育研究センター)

    2019年度

  • 演習(薬学教育研究センター)

    2019年度

  • 卒業研究A

    2019年度

  • 看護のための薬理学

    2019年度

  • 薬学英語演習U

    2019年度

全件表示 >>